Anoop is currently working at Columbia University Medical Center. Prior to this, he managed the IP portfolio at AgaMatrix, a company that makes blood glucose measurement devices for diabetics. Prior to that, he worked at Global Prior Art, an IP consulting company, where is jointly led the medical/surgical device group. His work included IP landscape development to assist in client’s strategic, technical and legal decision making; primarily focusing on minimally invasive cardiothoracic, orthopedic and GI surgery. While at MIT, he was a runner up at the $50K Entrepreneurship Competition, the President of a Cultural group and a Math tutor for a SAT outreach program. He was selected to be a 2008 Fellow in the Startup Leadership Program in Boston. He holds an MS from School of Engineering at MIT, and clinical training and research training from KMC, Mangalore and All India Institute of Medical Sciences (AIIMS), India. All along, his research work in computational biology and medicine was supported by several fellowships & scholarships.

Fellow since

Elena Chekhova, Founder & CEO, Biotine Consulting Elena is the founder of Biotine Consulting, a life science consultancy providing business development and project management services to life science companies in the US and internationally. Prior to founding Biotine, Elena served as Vice President of Business development at Chiral Quest, a manufacturing and technology start-up with offices in NJ and China. Previously Elena held positions in business development and project management at Pro-Pharmaceuticals, deCODE and Regis technologies. Earlier in her career, she worked for McKinsey and Bertelsmann AG in Germany. Elena completed her Ph.D in Chemical Engineer at MIT and University of Dortmund in Germany. She is a 2012 Fellow in the Startup Leadership Program in Boston.

Fellow since

Kimberly Homan is the Founder & Chief Technology Officer at NanoHybrids, a company focused on commercializing nano-sized contrast agents used to enable molecular imaging and theranostic approaches in cancer and atherosclerosis. Prior to NanoHybrids, she was a Captain at the United States Marine Corps. She is currenly also working as a Research Associate at the Wyss Institute for Biologically Inspired Engineering Harvard University. She is an expert in Nanoparticles, Biomedical Engineering and Nanotechnology. Kimberly was awarded the Roche Postdoctoral Fellowship in 2015. She holds a Bachelor's degree in Chemical Engineering and a Master's in Biomedical/Medical Engineering and a Ph.D. in Biomedical/Medical Engineering. She is 2015 Fellow in the Startup Leadership Program in Boston.

Fellow since

Neculai Archip is the Founder and CEO of Cranberry Peak Corp., a Software platform focused on improving patient-care team connectivity and on enhancing efficiency for healthcare providers. Prior to Cranberry Peak, he worked at Siemens Healthcare, where he was Associate Director. Neculai has also worked at Siemens Venture Capital, Harvard Medical School and Microsoft. He is an expert in Strategy, Medical Devices and Healthcare Information Technology. He holds a degree in Computer Science, Ph.D. in Computer Science and Medical Imaging and an MBA in Finance, Entrepreneurship and Venture Capital. He is 2015 Fellow in the Startup Leadership Program in Boston.

Fellow since

Fellow since

Sameer Sabir is a co-founder and President of MoMelan Technologies which was acquired by Kinetic Concepts. Sameer is a recent graduate of the Harvard-MIT Biomedical Enterprise Program (BEP), which consists of an MBA from the MIT Sloan School of Management, and an MS from the Harvard-MIT Division of Health Sciences and Technology (HST). During his time on the BEP program, Sameer focused his educational and extracurricular pursuits on entrepreneurship in the life sciences, as well as supplementing his scientific knowledge through taking a number of classes at the Harvard Medical School. He held several teaching assistant and leadership positions, including lead organizer of both the MIT Venture Capital and Private Equity Conference and the MIT Venture Capital Competition. Prior to the BEP program, Sameer was a co-founder and Director of Cinnabar Consulting. Cinnabar Consulting focused on helping early-stage life sciences companies in Scandinavia conduct business and corporate development activities in the USA. The operating model was to engage clients on a long-term basis and integrate into the operating team, which Sameer successfully achieved with his clients. Prior to Cinnabar Consulting, Sameer spent three years in life sciences investment banking with Commerzbank Securities and JPMorgan, focused on working with early stage life sciences companies. Sameer completed his undergraduate studies at University College London (UCL) where he took a BS.c degree in Immunology.

Fellow since

Sanjay is Medical Director of Neurology and Clinical Development at Genzyme and was a Research Fellow at the Children’s Hospital and Harvard Medical School. He has trained as a physician-scientist, and has published several research articles on neurobiology, neurology, bioinformatics and life sciences in leading journals. He has received awards and honors for excellence in research, and has been invited for technical presentations at national meetings. He was selected to be a 2007 Founding Fellow in the Startup Leadership Program in Boston. He is interested in the application of interdisciplinary knowledge resources towards identifying and executing innovative ideas towards improving accessibility to novel therapeutics and devices. An excellent communicator, with experience as a healthcare professional, he has effective problem-solving and organizational skills. Sanjay is passionate about application of translational technology solutions to healthcare industry.

Fellow since

Seth is a healthcare strategy consultant at Clearview Partners. Prior to this he was a consultant at Health Advances, LLC. He is an expert at assisting pharmaceutical, biotechnology, and medical device companies with product commercialization, market assessment, portfolio prioritization, and technology valuation. Prior to his work as a consultant, Seth received his PhD in Biology at the Massachusetts Institute of Technology. As part of his PhD, he created the first specific and controllable mouse model of human osteosarcoma to further the understanding of the disease and catalyze the development of new cancer therapies. Seth has also been a business development intern for PureTech Ventures, a venture firm committed to transforming breakthrough technologies into leading edge firms, and for BioScale, a Boston start-up developing nanotechnology for the identification and differentiation of chemical and biological materials. Seth graduated with a BS in Biochemistry and Economics from Rutgers University, where he was the leader of several undergraduate organizations. In his spare time he is a resident tutor for MIT undergraduates and enjoys playing several intramural sports, cooking, reading, and traveling to foreign countries.

Fellow since

Shinichiro Fuse, Director Business Development, Bluebird Bio. Shin is the Principal at MPM Capital. He is also an contributing writer for Nikkei Biotech, the leading biotech business journal in Japan. Prior to joining bluebird, he was an Engagement Manager in the Corporate Development team at Campbell Alliance, a life science consultancy. Prior to Campbell, he was an Associate at PureTech Ventures, where he was on the founding team of Vedanta Biosciences (a microbiome company) and Mandara Sciences (nutrition). He completed his Ph.D. (Microbiology & Immunology) from Dartmouth College and was an Albert J. Ryan Scholar. He also holds an M.S. from University of Tokyo (Medical Sciences) and B.E. from Keio University (Chemistry), Japan. He is a 2012 Boston Fellow and was the Global Lead for SLP's Education Team from 2013-2014.

Fellow since

Vikas Goyal is currently an Associate at SR One and was a manager in Corporate & Product Development at Infinity Pharmaceuticals, immediately after leaving Wharton. During business school he worked at SROne, the corporate venture arm of GlaxoSmithkline as was President of the Wharton Healthcare Club. Prior to leaving for business school, he was a founding member of Extera Partners (formerly PureTech Development), where he has led and supported the business development, M&A, and corporate strategy efforts of over 40 private and public life science companies. Previously, he was a consultant with McKinsey & Co, where he worked with top-tier pharmaceutical, medical device and consumer health companies around the world. Over his career, Vikas has supported the diligence, negotiations, and post-transaction management of multiple corporate partnerships, from multi-billion dollar M&A events to initial R&D collaborations. Vikas is a graduate of Harvard University, where he studied neurobiology and an MBA from Wharton. He has over seven years’ bench research experience in electrophysiology, and has worked with top investigators at the Rockefeller University and Boston University’s Center for Memory and Brain.

Fellow since

Weijie Poh is the Co-Founder of PathoVax LLC, a biotechnology startup commercializing a breakthrough Human Papillomavirus (HPV) vaccine developed at a prestigious research institution in Baltimore, Maryland. Prior to PathoVax, he worked at the Agency for Science, Technology and Research, where he was a Research Officer. Weijie has also worked at Vector BioLabs, Inc, and was a Infantry Training Officer (Lieutenant) for the Singapore Armed Forces. He is an expert in Molecular Biology,Cell and Biotechnology. He holds a degree in Engineering and Applied Sciences and Life Science (Concentration in Cell and Molecular Biology) and a Ph.D. in Pathobiology. He is 2015 Fellow in the Startup Leadership Program in Boston.

Fellow since

Will Adams is the Chief Scientific Officer and Co-founder at Riparian Pharmaceuticals, Inc. He has a Ph.D. from the Harvard School of Engineering and Applied Sciences. Will graduated cum laude from Harvard University with a B.S. degree in Engineering Sciences. He was selected to be a 2010 Fellow in the Startup Leadership Program in Boston. Will participated as an intern within the Cancer Bioscience division of AstraZeneca Pharmaceuticals and later received an M.S. in Applied Mathematics from Harvard University. He is interested in developing more sophisticated assays for higher fidelity preclinical drug testing.

Fellow since